OR WAIT 15 SECS
June 25, 2015.
The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36 in 2014, with their combined value rising from $122.8 million to $4.9 billion over the same period, reports research and consulting firm GlobalData.
The company’s latest report states that M&A activity is typically low in the gene therapy field, as the technology remains highly experimental and the majority of products are in early-stage clinical development.
Despite this, the impressive growth in the overall deals value for 2014 was boosted primarily by Abbott Laboratories’ $2.9 billion acquisition of Chilean biotech CFR Pharmaceuticals, and GlobalData analyst Adam Dion states that '[l]icensing and partnerships, together with capital raisings, have represented the largest number of gene therapy deals struck since 2009."
Dion goes on:“These deals include Bristol-Myers Squibb’s $1 billion licensing agreement with UniQure to develop S100AI [and] Voyager Therapeutics $845 million agreement with Genzyme to develop three Phase I programs concerning the central nervous system.”
“This rise in financial investment may be indicative of renewed investor confidence, and could lead to higher-than-expected deal activity for gene therapies in the future,” Dion concludes.